2012-05-18 0:12:33 - Не могу записать данные в файл: /home/indoor/public_html/cache_tnxx/cache_indoorenvirons_com_51.txt
The News Review:
- Travel Health: Jet Lag Cosmic Radiation and In-Flight Emergencies
- Genes Show Limited Value in Predicting Diseases
- Back in the Hospital Again
- Cell Biosciences Announces Publication in Nature Medicine
- Media scan
- Satoris And Raybiotech Announce Collaboration To Develop And …
- A Drop of Blood May Help Assess Cancer Therapy
Travel Health: Jet Lag Cosmic Radiation and In-Flight Emergencies
New York Times
Mark Gendreau answered readers’ questions on safe travel. Gendreau is senior staff physician and vice chair of emergency medicine at Lahey Clinic in Burlington Mass. and assistant professor of emergency medicine at the Tufts School of Medicine in Boston. His special interests include health issues associated with commercial air travel including transmission of infectious diseases. Do you have additional questions on air travel health? Post your questions in the comments section below.
Related from Wtgmarketingsummit: Green Globe International Announces Agreement With Global Travel …
Genes Show Limited Value in Predicting Diseases
New York Times
The genetic analysis of common disease is turning out to be a lot more complex than expected. Skip to next paragraph.
Back in the Hospital Again
New York Times
The more fundamental problem is the fragmented nature of the American medical system: too often health-care providers fail to communicate with one another patients fall between the cracks and no one seems clearly in charge of a patient’s welfare. A new analysis by three researchers published in The New England Journal of Medicine estimated that unplanned rehospitalizations among fee-for-service beneficiaries cost Medicare $17. 4 billion in fiscal year 2004 which is a big chunk of the $102. 6 billion that Medicare paid hospitals that year. Most patients were readmitted for problems other than those that led to their original hospitalizations. Surgical patients for example were typically readmitted for such medical conditions as pneumonia heart failure or bacterial infections.
Cell Biosciences Announces Publication in Nature Medicine
PR Newswire (press release)
Felsher Associate Professor of ncology was senior author on the study. The publication titled "Nano-fluidic proteomic assay for serial analysis of oncoprotein activation in clinical samples" appeared on April 12 2009 as an Advance nline Publication in the prestigious journal Nature Medicine. In this work the authors report on new methods for detecting small modifications in cancer-related proteins. Importantly the exceptional sensitivity of the methods enabled oncoprotein studies in extremely small tumor samples derived from cancer patients. This work was performed using a protein analysis system from Cell Biosciences.
Media scan
Indianapolis Star
She has practiced natural medicine for more than 30 years and is a medical school clinical instructor from New York. By correcting imbalances resulting from conditions such as food allergies hormone deficiencies and an underactive thyroid the tips in the book are designed to help you restructure your health — and lose weight. В» Now that we have an extra hour of light in the evening you might want some ideas for spending more time outside.
Satoris And Raybiotech Announce Collaboration To Develop And …
Emediawire (press release)
In the reported study researchers analyzed 259 stored blood samples comparing those from individuals with presymptomatic to late-stage Alzheimer's disease with those from individuals without the disease. Using a technique known as signal profiling that was enabled by RayBiotech Cytokine Antibody Arrays they were able to simultaneously measure the relative abundance of 120 known proteins found in plasma that function as chemical messengers between blood cells brain cells and cells of the immune system. Among the 120 plasma markers measured in the Nature Medicine study a panel of 18 exhibited an expression pattern that was statistically different in the Alzheimer's samples versus other samples. This panel of 18 biomarkers was used to predict the presence of the disease in a test sample set with nearly 90 percent accuracy. In the collaboration with RayBiotech the panel of 18 biomarkers will be applied to the proprietary RayBiotech Quantibody® array platform. After validating performance of the resulting array-based test it will initially be commercialized later this year as a research-use-only test to support Alzheimer's research and Alzheimer's drug development and clinical trials. RayBiotech will sell the test kit while Satoris will use the array together with proprietary bioinformatic analysis tools to offer a testing service.
Booking hotels? Find cheap hotels and save big.
A Drop of Blood May Help Assess Cancer Therapy
Forbes
Thestandard way we measure if a treatment is working is to waitseveral weeks to see if the tumor mass shrinks. It would really bea leap forward if we could detect what is happening at the cellularlevel" lead author Dr. Alice Fan a clinical instructor inthe oncology division at the Stanford University School of Medicinein California said in a school news release. "This technology allows us to analyze cancer-associatedproteins on a very small scale" senior study author Dr. DeanFelsher an associate professor of medicine and of pathology saidin the news release. "Not only can we detect picogram levels– one-trillionth of a gram — of protein but we can also see verysubtle changes in the ways the protein is modified. "Variations in the way a protein is modified can affect how itfunctions in tumor progression.
Leave a Comment